Latest lecanemab data to be presented at the AD/PD™ congress
News provided by
Share this article
Share this article
STOCKHOLM, March 5, 2021 /PRNewswire/ BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401), at the 15th International Conference on Alzheimer s and Parkinson s Diseases and related neurological disorders, AD/PD™ 2021.
The International Conference on Alzheimer s and Parkinson s Diseases and related neurological disorders - which due to the ongoing COVID-19 pandemic will be held online - is a key scientific event with a focus on improving the treatment of Alzheimer s, Parkinson s and other related neurodegenerative diseases.
Share this article
Share this article
HOUSTON, March 4, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment. We are excited to clinically explore the potential of one of our immunotherapy drug candidates, which is based on our proprietary adenovirus platform technology, in additional cancer indications, said Jeffrey Knapp, chief executive officer of DNAtrix. Our preclinical work with DNX-2440 has demonstrated that infection of human tumor cell lines with this agent leads to viral replication, high level expression of OX40 ligand on tumor cell
Maintaining Heart Function After a Heart Attack
News provided by
Share this article
WASHINGTON, March 4, 2021 /PRNewswire/ An article published in
Experimental Biology and Medicine (Volume 246, Issue 5, March, 2021) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220969844) reports a new therapeutic option for preventing long-term damage to the heart after a heart attack. The study, led by Dr. Y. James Kang, in the Regenerative Medicine Research Center at Sichuan University in Chengdu (China) and the Memphis Institute of Regenerative Medicine at the University of Tennessee Health Science Center in Memphis, TN (USA), reports that inhibition of the copper chaperone COMMD1 blocks myocardial injury and maintains heart function in a mouse model of myocardial ischemia.
Share this article
Share this article
OXFORD, England, Feb. 18, 2021 /PRNewswire/ Evox Therapeutics Ltd ( Evox or the Company ), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round.
The financing was significantly oversubscribed with high demand from both existing and new investors. The Series C financing was led by Redmile Group who were joined by new investors OrbiMed and Invus. In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments. Eli Lilly, also converted a $10 million convertible note, that formed part of our 2020 collaboration agreement with them, into equity as part of this round.